Tiziana Life Sciences PLC   | AIM:TILS


BOARD & SCIENTIFIC ADVISORY BOARD


Board of Directors


Gabriele Cerrone  MBA               Founder & Exec Chairman

As above - see Management


Riccardo Dalla-Favera  MD         Director

Dr Riccardo Dalla-Favera obtained his MD from the University of Milan, Italy in 1976. Following his residency in Haematology Dr Dalla-Favera joined the National Cancer Institute of USA as a visiting fellow. He joined the New York University of Medicine as an assistant Professor in 1983 and then moved to Columbia University College of Physicians and Surgeons in 1991. Here he helped to found the Institute for Cancer Genetics and has been its’ Director since 1999.

Dr Dalla-Favera was a Director of the Herbert Irving Comprehensive Cancer Centre (HICCC) from 2005 to 2011 and the Percy and Joanne Uris Professor of Pathology and Genetics & Development. He served as the Chair of the Scientific Advisory Board of the Yale Cancer Centre. He served as the Co-Chair of the National Centre Institute Program Review Group for Leukaemia, Lymphoma and Myeloma, as a member of the Board of Scientific Counsellors of the National Institute of Environmental Health and of the National Cancer Institute. He has been a Member of Scientific Advisory Board at TrovaGene, Inc., since April 2010. He serves as a Member of Scientific Advisory Board at Xigen SA. He serves as a Member of Scientific Advisory Board at Cancer Genetics, Inc. and served as its Director till 2011. Dr Dalla-Favera served as a Director of Callisto Pharmaceuticals Inc. from June 30, 2005 to April 15, 2011. He served as a Director at Synergy Pharmaceuticals, Inc. until April 2011.

Dr Dalla-Favera has been a leader in the field of molecular oncology and has made fundamental contributions to the field of cancer, especially in the study of the molecular genetics of B cell malignancies. As a researcher, he has contributed much of the current knowledge on the genetic lesions responsible for human B cell lymphoma, which have led to the development of diagnostic tests and are being tested as targets in clinical trials with lymphoma patients. His has been awarded numerous prizes for his research including the 2007 William Dameshek Prize from the American Society of Hematology, The 2009 San Salvatore Foundation Prize for Outstanding Achievements in Lymphoma Research, and the 2014 Oncomed Giants of Cancer Care Award. He is an elected member of Institute of Medicine of The National Academy of Sciences, USA.



Kunwar Shalubhai  PhD MBA               Director

Dr. Shailubhai is a Co-Founder and Chief Scientific Officer of Synergy Pharmaceuticals, Inc., a NASDAQ-listed biotechnology company focusing on innovative therapeutics for treatment of GI disorders, diseases and colon cancer. Dr. Shailubhai has held leadership positions at Monsanto Life Sciences Company (St. Louis, MO), Callisto Pharmaceuticals, and Synergy Pharmaceuticals Inc.  At Monsanto Company Dr. Shailubhai worked on a number of projects in inflammatory diseases and cancer, and eventually headed the cancer prevention group where he initiated research programs focusing on prevention of breast, prostate, and colon cancer in humans. He also initiated discovery projects to explore the therapeutic potential of uroguanylin, a physiological agonist of guanylate cyclase-C (GC-C), in GI disorders, diseases and colon cancer. These pioneering research efforts opened a novel avenue for therapeutic applications of uroguanylin and other GC-C agonists, not only in colon cancer but also in other GI diseases such as irritable bowel syndrome-constipation (IBS-C), chronic idiopathic constipation (CIC), and inflammatory bowel disease (IBD).  Dr. Shailubhai discovered several other proprietary GC-C agonists as part of the development of Synergy’s discovery portfolio. Dr. Shailubhai has 17 issued patents, several pending patent applications, and 40 research publications in journals of international repute. Dr. Shailubhai also holds joint appointments as Professor at Bharuch S. Blumberg Institute, Doylestown, PA and as an Adjunct Professor at Drexel University School of Medicine, Philadelphia. Dr. Shailubhai received his M.B.A. degree in 2002 from University of Missouri at St. Louis.



Willy Simon             Non-Executive Director

Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. From 2004 until 2012, he served as a non-executive director of Redi & Partners Ltd., a fund of funds. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2015 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company.


Scientific Advisory COMMITTEE


Prof. Napoleone Ferrara  MD

Dr Ferrara is Senior Deputy Director for Basic Sciences at University of California's Moores Cancer Center in San Diego; and Distinguished Professor of Pathology at the University of California's School of Medicine, also in San Diego. Dr Ferrara's research led to the development of the anti-VEGF monoclonal antibody bevacizumab (Avastin®) which was initially approved for the treatment of colorectal cancers, now one of the top ten selling global pharmaceutical products and won the 2010 Lasker Award for his work on VEGF.



Prof. Pier Paolo Di Fiore  MD PhD

Pier is a full Professor at the University of Milan, Italy and a Director of Molecular Medicine at the European Institute of Oncology. Pier is also the Senior Editor of The Journal of Cell Biology, and Associate Editor of Cell.



Dr Thomas Adams  PhD

Dr Thomas Adams has been a Director of Synergy Pharmaceuticals since July 2008 and is also the Chairman of TrovaGene, Inc. Dr Adams currently serves as a director of La Jolla Pharmaceutical Co. a publicly held company that develops and markets novel therapeutics for antibody-mediated autoimmune diseases. Since June 2005, Dr Adams has served as a director of IRIS International, Inc., a diagnostics company, and as Chief Technology Officer of IRIS since April 2006. Dr Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.



Professor Roberto Pellicciari  PhD

Prof. Roberto Pellicciari, Ph.D. was Scientific Co-Founder of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) ("Intercept"), a clinical stage biopharmaceutical company focused on the development and commercialisation of novel bile acid therapeutics to treat chronic liver and intestinal diseases. Intercept currently has a market capitalisation of approximately [US$6.15 billion,] and served as its Head of Medicinal Chemistry. Prof. Pellicciari served as a Member of the Scientific Advisory Board at Intercept Pharmaceuticals, Inc. and has been a Member of Scientific Advisory Board at Tiziana Life Sciences PLC since September 2014. He served as President of the Division of Medicinal Chemistry of the Italian Chemical Society from 2001 to 2003 and President of the European Federation of Medicinal Chemistry, EFMC from 2006 to 2008. Prof. Pellicciari is a Professor of Medicinal Chemistry, University Perugia and has been awarded several academic prizes, such as the "Domenico Marotta" prize of the "Accademia Nazionale delle Scienze" (1999), the "Mentzer" prize of the French "Societe de Chimie Therapeutique" (2001), the "Giacomello Medal" of the "Divisione di Chimica Farmaceutica (SCI)" (2006), the "Amedeo Avogadro Medal" of the Italian Chemical Society (SCI) (2009) and the “Pratesi Medal” of the "Divisione di Chimica Farmaceutica (SCI)" (2011). Prof. Pellicciari has an international reputation in molecular design, synthesis, mechanism of reaction, and modelling, with over 300 publications in international journals and 40 patents granted.



Professor Kevan Herold  MD

Dr. Kevan Herold is Professor of Immunobiology and of Medicine (Endocrinology) as well as Deputy Director, Yale Center for Clinical Investigation, Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale. His investigative work has focused on developing new ways to prevent and treat autoimmune diseases, using novel translational immunologic and metabolic approaches to prevent progression, in particular anti-CD3 monoclonal antibody therapy. His clinical interests are in the management of endocrine diseases, and he is involved in a number of national and international clinical studies of new treatments.



Professor Howard Weiner  MD

Dr. Howard Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumours. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases.

 

Management Team


Gabriele Cerrone MBA

James Tripp

Tiziano Lazzaretti MBA

Robert Evans PharmD



Scientific Founders


Andrea Brancale PhD

Richard Clarkson PhD   

Andrew Westwell PhD



Board of Directors


Gabriele Cerrone MBA, Chairman

Riccardo Dalla-Favera MD, Director

Kunwar Shailubhai, PhD MBA Director

Willy Simon, Non-Executive Director



Scientific Advisory Board


Prof. Napoleone Ferrara MD

Prof. Pier Paolo Di Fiore MD PhD

Dr Thomas Adams  PhD

Prof. Roberto Pellicciari  PhD

Prof. Kevan Herold MD

Prof. Howard Weiner MD